Jimenez, C., Chin, B. B., Noto, R. B., Dillon, J. S., Solnes, L. B., DiPippo, V. A., . . . Pryma, D. A. (2020). OR25-07 A Multi-Center, Open-Label, Pivotal Phase 2 Study of Azedra® (HSA I-131-MIBG) in Patients with Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma: Updated Long-Term Survival and Safety. J Endocr Soc.

Jimenez, Camilo, Bennett B. Chin, Richard B. Noto, Joseph Stephen Dillon, Lilja B. Solnes, Vincent A. DiPippo, Nancy Stambler, Vivien Wong, and Daniel A. Pryma. "OR25-07 A Multi-Center, Open-Label, Pivotal Phase 2 Study of Azedra® (HSA I-131-MIBG) in Patients With Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma: Updated Long-Term Survival and Safety." J Endocr Soc 2020.

Jimenez, Camilo, et al. "OR25-07 A Multi-Center, Open-Label, Pivotal Phase 2 Study of Azedra® (HSA I-131-MIBG) in Patients With Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma: Updated Long-Term Survival and Safety." J Endocr Soc 2020.